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ABSTRACT
Objective We investigated discrimination and
calibration of cardiovascular disease (CVD) risk scores
when genotypic was added to phenotypic information.
The potential of genetic information for those at
intermediate risk by a phenotype-based risk score was
assessed.
Methods Data were from seven prospective studies
including 11 851 individuals initially free of CVD or
diabetes, with 1444 incident CVD events over 10 years’
follow-up. We calculated a score from 53 CVD-related
single nucleotide polymorphisms and an established CVD
risk equation ‘QRISK-2’ comprising phenotypic measures.
The area under the receiver operating characteristic curve
(AUROC), detection rate for given false-positive rate
(FPR) and net reclassiﬁcation improvement (NRI) index
were estimated for gene scores alone and in addition to
the QRISK-2 CVD risk score. We also evaluated use of
genetic information only for those at intermediate risk
according to QRISK-2.
Results The AUROC was 0.635 for QRISK-2 alone and
0.623 with addition of the gene score. The detection
rate for 5% FPR improved from 11.9% to 12.0% when
the gene score was added. For a 10-year CVD risk cut-
off point of 10%, the NRI was 0.25% when the gene
score was added to QRISK-2. Applying the genetic risk
score only to those with QRISK-2 risk of 10%–<20%
and prescribing statins where risk exceeded 20%
suggested that genetic information could prevent one
additional event for every 462 people screened.
Conclusion The gene score produced minimal
incremental population-wide utility over phenotypic risk
prediction of CVD. Tailored prediction using genetic
information for those at intermediate risk may have
clinical utility.
INTRODUCTION
Despite the importance of predicting future cardio-
vascular disease (CVD) among initially healthy
adults, predictive accuracy has often seemed disap-
pointing, as most individuals who eventually suffer
a CVD event were previously at average risk rather
than high risk: the prevention paradox.1 Lowering
cholesterol through statin use reduces CVD risk.2
Accordingly, several major guidelines3–6 recom-
mend lipid-lowering therapy for people with a
raised 10-year CVD predicted risk, traditionally
using a threshold of 20%. However, with recent
patent expiries resulting in reduced acquisition
cost, and increasing evidence on the limited harms
of statins, the 10-year CVD risk threshold for
primary prevention of CVD has been reduced to
10% in the UK3 and to 7.5% in the USA.4
However, these decisions have been questioned,
especially since people with intermediate 10-year
CVD risk (eg, 10%–20%) may be reluctant to
undergo statin therapy.5 Reﬁning risk estimation
may be of particular interest in such individuals, as
well as helping guide appropriate targeting of alter-
native therapies currently under development.
Considerable advances have taken place in under-
standing genetic determinants of CVD in recent
years and the CardiogramPlusC4D collaboration
have now catalogued associations of hundreds of
thousands of single nucleotide polymorphisms
(SNPs) across the genome, using data on over
63 000 coronary heart disease (CHD) cases and
130 000 controls.6 This collaboration identiﬁed 46
loci containing SNPs that surpassed genome-wide
levels of statistical signiﬁcance. Further SNPs asso-
ciated with ischaemic stroke risk have included
rs783396 from the AIM1 gene in chromosome
6q217 and rs12425791 (closest gene NINJ2,
chromosome 12).8 Case-control studies do not
permit estimation of absolute risk. We, therefore,
evaluated the predictive performance of a gene
score based on 53 SNPs associated with CHD or
stroke on its own and in conjunction with the
established non-genetic QRISK-2 risk tool9 (devel-
oped for CVD prediction in UK populations), using
the University College-London School-Edinburgh-
Bristol (UCLEB) Consortium of prospective popu-
lation studies.10
METHODS
UCLEB Consortium
A full description of the UCLEB Consortium has
been previously published.10 Brieﬂy, the studies
comprise individuals almost exclusively of European
ancestry from a wide geographical range within the
UK. For the current analysis, seven prospective
studies with genotype and complete information
on CVD incidence were included. For full details
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of individual studies, see online supplementary information. In
four of the studies (Edinburgh Artery Study (EAS), MRC
National Study of Health and Development (NSHD), Whitehall
II study (WHII) and Caerphilly Prospective study (CaPS)), all
participants providing blood samples were genotyped, but a
nested case-control sample was used for the remainder. Analysis
was restricted to 11 851 individuals aged ≤85 years and
excluded 1542 individuals with prevalent diabetes and 1191
with prevalent CVD.
Informed consent was obtained for all subjects included in
UCLEB research. Written approval from individual Research
Ethics Committees to use anonymised individual-level data has
been obtained by each participating study.
Clinical characteristics of the participants
Within individual cohorts, biochemical measurements were
performed in accredited laboratories using international stan-
dards.10 For the current analysis, earliest available measurements
were abstracted for each study on relevant phenotypes.
Medication data included lipid-lowering drugs (statins or other)
and blood pressure-lowering drugs; for the latter, adjustment
was made by adding 15 mm Hg for systolic and 10 mm Hg for
diastolic blood pressure.11
Deﬁnition of CVD
The deﬁnition of prevalent CVD (from the same time point as
the phenotypic measurements) was based on either self-report,
medical record review or examination with ECG. CVD con-
sisted of a combination of CHD and stroke. CHD included all
non-fatal myocardial infarction or any revascularisation proced-
ure (coronary artery bypass surgery or angioplasty) and fatal
CHD. Stroke included all non-fatal stroke (ischaemic and haem-
orrhagic combined, but excluding transient ischaemic attacks)
and fatal stroke. Fatal events were classed according to
International Classiﬁcation of Diseases-10 codes: I20–I25 for
CHD and I60–I69 for stroke.
Genotyping
DNA was extracted from blood samples either collected at base-
line (British Women’s Heart and Health Study (BWHHS)) or at
a subsequent resurvey (British Regional Heart Study (BRHS),
MRC NSHD, EAS, WHII, English Longitudinal Study of
Ageing (ELSA), CaPS).10 Genotype data were based on the
Illumina CardioMetabochip, which incorporates approximately
200 000 SNPs from loci previously identiﬁed for associations
with cardiometabolic disease risk factors and outcomes.12
Imputation was conducted against the 1000 genomes reference
panel, providing information on approximately 2 million typed
or imputed SNPs. Duplicate samples were genotyped to
compute the error rate. Quality control on genotyped samples
has been previously reported10 and all included SNPs had a call
rate of >98%. Genotypes were in Hardy Weinberg Equilibrium
in all studies.
We used the list of CVD-risk SNPs recently identiﬁed in large
meta-analyses of CHD6 and stroke7 8 (see online supplementary
ﬁle, eTable 1); all 53 CVD SNPs except one were typed through
the CardioMetabochip: one SNP associated with stroke
(rs783396) was imputed.
Statistical analysis
Score construction
We used the QRISK-2 2014 batch processor, using data for age,
sex, smoking, family history of CVD, body mass index, blood
pressure, treatment for hypertension, total and high-density
lipoprotein (HDL)-cholesterol, to compute the QRISK-2 risk
probabilities.9 We computed a genetic risk score (GRS) weighted
according to published coefﬁcients (log ORs) for the 53 SNPs.6
Coefﬁcients were multiplied by 0, 1 or 2, according to the
number of risk alleles carried by each person. The logits of the
QRISK-2 probabilities were added to the GRS to produce a
combined score. As a sensitivity analysis, to address concerns
that β-coefﬁcients for the individual SNPs selected for the GRS
may be inﬂated, we calculated an unweighted gene score and
followed similar procedures.
Association testing
Logistic regression models were ﬁtted to obtain the OR per SD
increase in the GRS as well as OR associated with each quintile.
Association models were ﬁtted using the combined dataset with
a term for study included as a ﬁxed effect.
Model discrimination
We calculated the area under the receiver operating characteris-
tic curve (AUROC) and the detection rate, deﬁned as the pro-
portion of all cases detected for a false-positive rate (FPR) of
5% (DR5) and 10% (DR10). AUROCs were calculated separ-
ately for each study and combined using both ﬁxed effects and
random effects meta-analysis. Improvements in discrimination
were assessed by calculating the difference between the two
AUROCs in each study with bootstrap estimates of the CI and
then combining these over the studies.
Model calibration
For the combined score, estimates of risk were obtained by con-
verting the logit back to a probability. For all studies but ELSA,
the number of events occurring within 10 years of baseline was
observed. For ELSA, since follow-up was for 5 years only, we
doubled this to give the 10-year observed risk. Observed risks
were then compared with predicted risks within tenths of the
predicted risk distribution and the Hosmer-Lemeshow test was
used to assess goodness of ﬁt.
Reclassiﬁcation of CVD risk
We used the net reclassiﬁcation improvement (NRI) index to
evaluate improvement in risk prediction. This metric quantiﬁes
the extent to which the combined score moved people to risk
categories that better reﬂected their future event status.13 In
three of the studies, all cases were genotyped but only a fraction
of the controls so it was necessary to upweight data for controls
to reﬂect properly the proportion of cases in the population.
For example, if within a particular age group of one study, only
80% of controls had been selected for genotyping, we assigned
a weight of 1.25 (=100/80) to all those controls but a weight of
1 to cases, when calculating the number who had been reclassi-
ﬁed. We used three 10-year CVD risk categories (<10%, 10%–
19.9% and 20% or higher). We calculated the NRI without
accounting for study and then calculated NRI and its standard
error for each study and combined it to an overall NRI with a
ﬁxed-effects meta-analysis. As there was very little difference in
the two methods, we present results for the latter.
We also followed the Emerging Risk Factors Collaboration’s
method14 in assessing additional predictive value of novel risk
factors for individuals initially categorised as intermediate risk
according to established risk factors. Of those whose predicted
risk was between 10% and 20% according to the QRISK-2
equation, we calculated the number who would subsequently be
reclassiﬁed as high risk once the GRS was added. We assumed
all such individuals would be treated with statins and would
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achieve a 20% relative risk reduction (adherence assumed to be
similar to that seen in trials2) and from this we estimated
the absolute number of cardiovascular events that might be pre-
vented. This enabled us to calculate the number needed to
screen to prevent one event.
All analysis was conducted using Stata (V.13.1; StataCorp,
Texas, USA).
RESULTS
Characteristics of the study participants
Studies differed by sex and age (table 1). A total of 1444 indivi-
duals out of 11 851 (1054 CHD events, 390 strokes) experi-
enced CVD within 10 years of follow-up (ﬁgure 1). A total of
297 events were fatal. The 10-year CVD event rates varied by
study, from 4.7% in NSHD (mean age 53 years at baseline of
follow-up) to 37.2% in EAS (mean age 64.2 years). Only 165
of the participants (1.4%) were on statin treatment at the start
of follow-up.
GRS and association with CVD risk factors and CVD events
Not every SNP demonstrated similar associations with CVD in
the UCLEB data to those previously published (see online sup-
plementary ﬁle, eTable 1), with ORs <1 for 14 of the 53 SNPs
in the UCLEB data.
There was a clear positive relationship of the GRS with total
cholesterol and an inverse relationship with HDL cholesterol
(see online supplementary ﬁle, eTable 2). These associations
attenuated when eight SNPs related to low-density lipoprotein
concentration were excluded from the gene score. Only a very
modest positive association was seen with reported family
history.
ORs of incident CVD for successive quintiles of the GRS
compared with the lowest quintile were 0.88, 1.10, 1.12 and
1.15, respectively, with an OR of 1.09 per SD increase (95% CI
1.03 to 1.15, p=0.005). Restricting incident CVD cases to 137
fatal events within 10 years, the OR for the GRS per SD
increase was 1.03 (95% CI 0.87 to 1.22, p=0.74). When con-
sidering prevalent CVD cases, the equivalent OR was 1.17
(95% CI 1.10 to 1.25, p=8.2×10−7). The relationship of the
QRISK-2 score with all incident CVD events was much stronger
(OR per SD increase 1.92: 95% CI 1.78 to 2.08, p=2.6×10−58).
Predictive accuracy of the GRS alone and in combination
with QRISK-2
Table 2 shows the AUROCs, for the GRS (0.524) and QRISK
(0.635) alone and the two in combination (0.623; see also
online supplementary ﬁle, eTable 3), as well as the detection
rates for 5% and 10% FPRs. These AUROC estimates were
Table 1 Characteristics of participants in the seven studies
BRHS BWHHS CaPS EAS ELSA NSHD WHII Total
Total 2138 1631 1121 632 1184 2330 2815 11 851
Follow-up (years) 10 10 10 10 ∼5 10 10
CVD events during follow-up (n) 205 268 119 235 142 109 366 1444
10-year CVD event rate
(per 100 person-years)
8.4* 11.4* 14.7 37.2 20.8*† 4.7 15.2 13.6
Predicted 10-year CVD risk (QRISK-2)
(per 100 person-years)
8.4 26.7 18.1 20.6 30.2 10.7 8.2 15.1
Age (years) 48.9 (5.6) 70.7 (5.3) 56.7 (4.4) 64.2 (5.7) 71.5 (8.5) 53.0 (0.0) 48.8 (6.0)
Sex, % male 100 0 100 46.4 51.9 49.4 77.2
Ever smokers (%) 33.1 46.0 80.5 22.6 64.1 72.5 48.3
Family history of CVD (%) – 58.2 – 67.6 5.3 63.0 51.6
Townsend score 0.355 (3.21) −0.21 (0.91)
Body mass index (kg/m2) 25.4 (2.9) 27.4 (4.8) 26.5 (3.6) 25.2 (3.6) 27.3 (4.2) 27.2 (4.5) 25.1 (3.5)
Total cholesterol (mmol/L) 6.36 (1.04) 6.79 (1.21) 5.61 (0.98) 7.08 (1.32) 6.12 (1.21) 6.12 (1.05) 6.44 (1.16)
Systolic blood pressure (mm Hg) 144.1 (20.2) 154.0 (27.0) 146.0 (22.3) 144.6 (25.1) 144.6 (19.6) 137.7 (21.1) 121.3 (14.0)
Treated hypertension (%) 2.2 28.6 – 16.8 36.0 11.6 5.8
Calendar years for baseline data collection 1978–1980 1999–2001 1984–1988 1987–1988 2004–2005 1999 1992–1993
Mean (SD) tabulated for continuous variables, percentage for binary variables.
*Adjusted for nested case-control study design, accounting for sampling fraction of controls.
†In ELSA, follow-up was for 5 years so the observed number of events was doubled for the 10-year rate.
CVD, cardiovascular disease.
Figure 1 Flow chart showing the selection of participants for
analysis. CVD, cardiovascular disease.
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virtually identical when family history data were not used for
the QRISK-2 score and also when random effects instead of
ﬁxed-effects analysis was used to combine studies’ results.
Detection rates for 5% and 10% FPRs were 6.8% and 13.1%,
respectively, for the GRS alone. The corresponding detection
rates for QRISK-2 were 11.9% and 21.2%, changing to 12.0%
and 19.6%, respectively, when the GRS was added.
Figure 2 shows that although QRISK-2 was well calibrated
with observed risk over the majority of the risk distribution, it
modestly underpredicted at low levels of risk and substantially
overpredicted risk for those in the top three tenths of the pre-
dicted risk distribution. Adding information from the GRS had
little effect on calibration: both predictive scores departed sig-
niﬁcantly from being well calibrated (χ 28=309.0 for QRISK-2
and 427.1 for QRISK-2+GRS by the Hosmer-Lemeshow test).
Reclassiﬁcation
NRI indices are shown in tables 3 and 4 according to whether
individuals were above or below 10% predicted risk (table 3)
and whether individuals were above or below 20% predicted
risk (table 4). For those who did not actually experience an
event, extra 2.33% individuals crossed the threshold downwards
rather than upwards when the GRS was added to the QRISK-2
equation. For those who did experience an event, extra 2.08%
individuals crossed the threshold downwards rather than
upwards when the GRS was added. Overall, the NRI was there-
fore 0.25% (95% CI −1.33% to 1.83%). When a threshold of
20% was used, a net increase of 0.90% was observed for those
who crossed the threshold downwards rather than upwards
among those who did not experience events and also a net
increase of 0.25% in the same direction for those who did
experience events. Hence the NRI was 0.65%.
Estimated performance of a sequential screening strategy
Figure 3 illustrates the estimated effect of a sequential screening
strategy applied to 100 000 people screened for CVD risk using
QRISK-2 followed by addition of information from a GRS
among those estimated to be in the intermediate-risk category
(10 year risk 10% to <20%). Based on QRISK-2 estimates, for
every 100 000 people in the population from which our data
were drawn, 29 445 would be at intermediate risk. When
adding the GRS, 16 782 would remain as intermediate risk,
7229 would be reclassiﬁed as low risk and 5434 would be
reclassiﬁed as high risk, thus making them eligible for statin
treatment. Based on extrapolation from the current analysis of
those reclassiﬁed by addition of the GRS, an estimated 1082
would go on to suffer a CVD event within 10 years. Assuming a
20% reduction in events from statin treatment, 216 events
(20% of 1082) would be expected to be prevented. Therefore,
adding information from the GRS to QRISK-2 among those
classiﬁed as being at intermediate risk by the latter would post-
pone one event for every 462 screened.
Potential inﬂuence of age on screening performance
Discrimination and reclassiﬁcation was estimated separately for
participants aged under 60 and over 60 (see online supplemen-
tary ﬁle, eTables 4–6). There was no evidence of any differences
in AUROC for the GRS alone (0.530 and 0.518, respectively),
in the improvement in AUROC of GRS compared with QRISK-2
alone (−0.010 and −0.007, respectively), NRI based on the 10%
cut-off point for predicted risk (0.60% for each age group) or
NRI based on the 20% cut-point (1.0% and 1.5%).
DISCUSSION
Our study suggests that gene scores from 53 SNPs were not
effective in predicting 10-year risk of CVD, with an area under
the curve of only 0.524; this area was 0.635 for a model with
QRISK-2 alone and 0.623 when a GRS was added in the
model. Nevertheless, the GRS appeared to carry some utility
when applied only to those who, according to conventional risk
scoring, would have been classiﬁed at intermediate risk, by
moving some individuals into the high-risk category. Among
100 000 people from a population represented by our combined
studies, 29 445 would be classed as of intermediate risk accord-
ing to the QRISK equation, but of these, 5434 would then be
reclassiﬁed as high risk once the GRS was applied and 1082
would suffer a CVD event if untreated with statins. For 20% of
these (216 people), treatment with statins according to guide-
lines could postpone the CVD event, leaving a number needed
to screen of 462 to postpone one CVD event. Recent evidence
suggests that the risk reductions from statin therapy might be
enhanced for those at highest risk,15 so this ﬁgure may be
conservative.
Our data include seven British prospective studies, in which
CVD events were deﬁned in a standard manner,10 genotyping
followed a common protocol and almost 1500 incident CVD
events were available for analysis. The participants of the studies
Table 2 Area under the receiver operating characteristic curve (AUROC) (95% CI) and detection rates for the combined data
AUROC for combined studies Detection rate for 5% false-positive Detection rate for 10% false-positive
Externally weighted gene score 0.524 (0.508 to 0.541) 6.8% (5.5 to 8.1) 13.1% (11.3 to 14.8)
QRISK-2 0.635 (0.619 to 0.650) 11.9% (10.3 to 13.6) 21.2% (19.1 to 23.3)
QRISK-2+
Externally weighted gene score
0.623 (0.608 to 0.639)
p=0.06*
12.0% (10.3 to 13.6) 19.6% (17.5 to 21.6)
*p Value derived from the comparison with QRISK-2 alone, estimated difference (95% CI)=−0.008 (−0.017 to 0.000).
Figure 2 Calibration shown by plot of observed and predicted
probabilities of cardiovascular disease within 10 years when predicted
risk distribution was divided into tenths. Results are shown for QRISK-2
prediction score and QRISK-2 combined with genetic risk score.
4 Morris RW, et al. Heart 2016;0:1–8. doi:10.1136/heartjnl-2016-309298
Cardiac risk factors and prevention
group.bmj.com on September 22, 2016 - Published by http://heart.bmj.com/Downloaded from 
were a median of 53 years and more commonly male. This age
group represents a population group most eligible for cardiovas-
cular screening and we did not see differential performance of
the screening algorithms according to age group, even when we
restricted analysis to those aged ≤53 (data not shown). Genetic
information may be more useful for those aged <40 (not repre-
sented in this study), but a lifetime risk equation would then be
required. In all seven studies combined, we noticed substantial
overprediction by QRISK-2, despite its apparently good calibra-
tion in other UK-based prospective studies.16 Thus, while we
noted that a two-stage screening procedure would yield identiﬁca-
tion and treatment of some high-risk individuals who would have
been classiﬁed at intermediate risk by QRISK-2, the phenomenon
of overprediction by QRISK-2 suggests that many more needed
to be reclassiﬁed as low risk. The genetic score did not actually
improve the calibration at all.
In constructing the GRS, we used regression coefﬁcients cata-
logued by the CardiogramplusC4D consortium on a very large
dataset. While the regression coefﬁcients for SNPs extracted
from this dataset will perform less optimally when applied to a
new dataset, we believe this represents a truer test of valid-
ation.17 The 53 SNPs will probably be those SNPs most strongly
associated with CVD that will ever be found, but their com-
bined effect still represents a small proportion of heritability of
CVD and is still small compared with major phenotypic risk
factors. Better prediction from genotypic information may be
expected from identiﬁcation of several thousand more SNPs.18
The development of QRISK-2, and most of our studies’ base-
lines, pre-dated the statin era and the proportion taking statins
during follow-up would be modest. Our data are capable of
evaluating what risks could have been prevented had statins
been widely available.
Table 3 Net reclassification index (NRI) based on addition of gene score to QRISK, calculated using 10% risk cut-off
No. of people
QRISK+externally weighted
gene score
NO CVD (n=15928.64*) Reclassified
Predicted risk QRISK <10 ≥10 Increased risk Decreased risk Net correctly reclassified
<10
≥10
5475.02
1156.07
785.56
8511.99
785.56 1156.07 2.33% (1.8 to 2.9)
QRISK+externally weighted
gene score
CVD (N=1697.81*)
Predicted risk QRISK <10 ≥10
<10
≥10
352.27
100.58
65.36
1179.60
65.36 100.58 −2.07 (−3.56 to −0.59)
NRI (95% CI)†
NRI (95% CI)‡
0.25% (−1.33 to 1.83) p=0.76
1.18% (−0.23 to 2.60) p=0.10
*Numbers inflated due to extra weighting assigned to three studies where samples of controls were taken (see statistical analysis section).
†No adjustment for study.
‡Results from meta-analysis of individual study results (fixed effects).
CVD, cardiovascular disease.
Table 4 Net reclassification index (NRI) based on addition of gene score to QRISK, calculated using 20% risk cut-off
No. of people
QRISK+externally weighted
gene score
NO CVD (N=15928.64*) Reclassified
Predicted risk QRISK <20 ≥20 Increased risk Decreased risk Net correctly reclassified
<20
≥20
9789.24
927.36
783.85
4428.19
783.85 927.36 0.90% (0.39 to 1.41)
QRISK+externally weighted
gene score
CVD (N=1707.7*)
Predicted risk QRISK <20 ≥20
<20
≥20
605.5
124.3
146.1
831.9
146.1 124.3 −0.25% (−2.09 to 1.58)
NRI (95% CI)†
NRI (95% CI)‡
0.65% (−1.26 to 2.55) p=0.51
0.68% (−1.16 to 2.52) p=0.47
*Numbers inflated due to extra weighting assigned to three studies where samples of controls were taken (see statistical analysis section).
†No adjustment for study.
‡Results from meta-analysis of individual study results (fixed effects).
CVD, cardiovascular disease.
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Other attempts to evaluate use of genotypic data for cardio-
vascular risk screening have been made. A marginal improve-
ment in discrimination over and above the predictive power of
traditional coronary risk factors was found in the ARIC study
for African-American participants (but less clearly for Caucasian
participants)19 and among European men.20 Among participants
of the Framingham study, no signiﬁcant improvement in dis-
crimination was found but a modest beneﬁt in reclassiﬁcation of
CVD risk.21 The Framingham study and the REGICOR study
(north-eastern Spain, low CHD risk) were used to assess CHD
risk: this showed that a GRS improved discrimination for
Framingham participants but not REGICOR.22 However, better
performance was seen for reclassiﬁcation of those at intermedi-
ate risk in both studies. The same was true in the FINRISK
studies,23 which estimated with a two-stage screening that 135
events could be prevented among 100 000 screened, slightly less
than 216/100 000 in the present study.
Recent data from the Malmὂ Diet and Cancer Study showed
that family history did not lessen the predictive utility of a
GRS, but the GRS added predictive value over phenotypic risk
scores which included family history.24 In contrast, our data
ﬁnd little evidence for improvement in discrimination over a
phenotypic risk score, whether or not it includes family
history.
The Rotterdam study25 conducted similar GRS analysis using
the same subset of 53 SNPs as in the present study. As in our
study, a stronger relationship of gene score was observed for
prevalent cases than incident. The present study also observed a
weaker relationship of gene score with CVD mortality, thereby
supporting the suggestion that some genes identiﬁed by
CardiogramplusC4D were related to better survival after CVD,
rather than to incident disease, and questions the generation of
signals through genome-wide association studies in case-control
studies, if no distinction can be made between cases who have
died and those who survived. A fully powered prospective study
is required of individuals with incident CVD, to compare geno-
types between survivors and those who died of the event.
Our ﬁndings underline the relatively disappointing perform-
ance of gene scores in adding to cardiovascular risk scores based
on established risk factors. Nevertheless, we have shown the
potential for reﬁning risk calculation in those initially classed as
of intermediate risk. A similar analysis applied to selective use of
C reactive protein and ﬁbrinogen in those at intermediate risk
suggested that these markers would require over 3000 screened
to postpone a CVD event:14 the relatively better performance of
the GRS in the present study is because a higher proportion of
those at intermediate risk were reclassiﬁed as high risk. It has
been shown that a collection of alternative risk scores (including
QRISK-2), based on established risk factors, are liable to disagree
over classifying individuals as high risk.26 Therefore including a
GRS may help identify an intermediate group who should prop-
erly be classed as of high risk. Despite current UK recommenda-
tions that treatment with statins be extended to those at
Figure 3 Flow chart showing the
modelling of reclassiﬁcation using
Gene Score. CVD, cardiovascular
disease.
Key messages
What is already known on this subject?
▸ Predictive accuracy of cardiovascular risk, generally based on
well-established phenotypic measures, has often seemed
disappointing. Genome-wide association studies have
highlighted new genetic loci related to coronary artery
disease and stroke.
What might this study add?
▸ When information on 53 single nucleotide polymorphisms
about individuals from seven UK prospective studies are
added to a well-established cardiovascular risk score, the
ability to predict cardiovascular disease (CVD) over the next
10 years is not enhanced.
▸ However, if a genetic risk score is applied to individuals
classed at intermediate risk according to a traditional risk
score, some individuals will be reclassiﬁed at high risk and
CVD events will be postponed due to timely use of
lipid-lowering therapy. This two-stage strategy will postpone
216 events in every 100 000 people screened.
How might this impact on clinical practice?
▸ Routine use of genetic proﬁles is not necessary for everyone
screened for cardiovascular risk. However, there may be
clinical utility for a genetic risk score for those initially
screened as of intermediate risk.
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intermediate risk3 (CVD risk 10–20% over 10 years) as well as
those at high risk (over 20%), family physicians may be reluctant
to do so. The Joint British Societies’ ( JBS3) consensus recom-
mendations for the prevention of CVD did not recommend the
use of genetic information, which was seen as currently perform-
ing less well than established risk factors.27 However for indivi-
duals not meeting the criteria for lifestyle or drug therapy, JBS3
recommended calculation of metrics such as heart age, relating to
lifetime risk. A gene score with good predictive power would
seem particularly suitable to evaluate lifetime risk, given its non-
modiﬁable nature throughout the life course.
The Rotterdam study25 constructed a second risk score based
on 169 SNPs including the original 53 modelled in our study, as
well as a further 116 for whom only modestly signiﬁcant
changes in risks were demonstrated. This second risk score per-
formed better than the ﬁrst and further gene discovery may
therefore produce greater improvements. However, at present,
our results and those of others cannot support the population-
wide use of GRSs in targeting treatment, despite the modest
utility in reclassifying those at intermediate risk.
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